# EDGAR Filing Document

**Accession Number:** 0001651625
**File Stem:** 0000950103-26-004156
**Filing Date:** 2026-3
**Character Count:** 8935
**Document Hash:** 21b0bba1848011ca68696aa230ac371a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950103-26-004156.hdr.sgml**: 20260318

**ACCESSION NUMBER**: 0000950103-26-004156

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260318

**DATE AS OF CHANGE**: 20260318

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Buetler Monika
- **CENTRAL INDEX KEY:** 0002115138

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37891
- **FILM NUMBER:** 26767371

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** BACHTOBELSTRASSE 44
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8
- **ZIP:** 8045
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AC Immune SA
- **CENTRAL INDEX KEY:** 0001651625
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** EPFL INNOVATION PARK, BUILDING B
- **CITY:** 1015 LAUSANNE
- **STATE:** V8
- **ZIP:** 00000
- **BUSINESS PHONE:** 41 21 345 91 21

**MAIL ADDRESS:**
- **STREET 1:** EPFL INNOVATION PARK, BUILDING B
- **CITY:** 1015 LAUSANNE
- **STATE:** V8
- **ZIP:** 00000

## Ex-24

**Exhibit 24** 

**POWER OF ATTORNEY**

Know all by these presents, that the undersigned hereby constitutes and appoints each of **Christopher Roberts, Tim Kay and Matthias Maurer** as the undersigned's true and lawful attorneys-in-fact to:

&nbsp;&nbsp;&nbsp;&nbsp;1. obtain and maintain credentials, including any Form ID or amended
Form ID, to enable the undersigned, directly or indirectly including through a delegated entity, account administrator or other designated
filing agent, to submit and file information and documents via the SEC's Electronic Data Gathering and Retrieval **("EDGAR")** system or successor EDGAR Next, including identification codes, verification codes, passwords and password management codes, and
any related annual ce1tifications or confirmations, and to act as the undersigned's agent for such purposes;

&nbsp;&nbsp;&nbsp;&nbsp;2. execute for and on behalf of the undersigned, in the undersigned's
capacity as a reporting person pursuant to Section 16 of the Securities Exchange Act of 1934, as amended (the **"Exchange Act"),** and the rules thereunder of AC Immune SA (the **"Company"),** Forms 3, 4 and 5, including any amendments thereto, in
accordance with Section 16(a) of the Exchange Act;

&nbsp;&nbsp;&nbsp;&nbsp;3. do and perform any and all acts, directly or indirectly including
through a delegated entity, account administrator or other designated filing agent, for and on behalf of the undersigned which may be
necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and
timely file such form with the United States Securities and Exchange Commission (the **"SEC")** and any applicable stock
exchange or similar authority;

&nbsp;&nbsp;&nbsp;&nbsp;4. prepare, execute and file, or cause to be prepared, executed
and filed, on behalf of the undersigned one or more Forms 144, or any amendments thereto, relating to any sales orders (including in
connection with the exercise of options to purchase the Company's common stock **("common stock"),** orally or electronically,
to sell shares of common stock to the public from time to time in accordance with Rule 144 under the Securities Act of 1933, as amended;
and

&nbsp;&nbsp;&nbsp;&nbsp;5. take any other action of any type whatsoever in connection with
the foregoing which, in the opinion of any of such attorneys-in-fact, may be of benefit to, in the best interest of, or legally required
by, the undersigned, it being understood that the documents executed by any of such attorneys-in-fact on behalf of the undersigned pursuant
to this Power of Attorney shall be in such form and shall contain such terms and conditions as any of such attorneys-in-fact may approve
in the discretion of any of such attorneys-in-fact.

The undersigned hereby grants to each such attorney-in-fact full power and authority to act separately and to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution, delegation or revocation, hereby ratifying and confirming all that any of such attorneys-in-fact, or the substitute or substitutes or delegee or delegees of any of such attorneys-in-fact, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 12<sup>th</sup> day of February, 2026.

---

| | |
|:---|:---|
| Signature: | /s/ Monika Buetler  |
| Name: | Monika Buetler  |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Buetler Monika<br><sub>(Last) (First) (Middle)</sub><br>EPFL INNOVATION PARK, BUILDING B<br><sub>(Street)</sub><br>LAUSANNE, SWITZERLAND 1015<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>AC Immune SA [ ACIU ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Shares | 53905<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Share Option (right to buy) | <sup>(2)</sup> | 2031-12-09 | Common Shares | 14310 | $5.31 | D |  |
| Share Option (right to buy) | <sup>(2)</sup> | 2032-06-23 | Common Shares | 56204 | $3.15 | D |  |
| Share Option (right to buy) | <sup>(2)</sup> | 2033-06-23 | Common Shares | 39823 | $2.15 | D |  |
| Share Option (right to buy) | <sup>(2)</sup> | 2034-06-30 | Common Shares | 15501 | $4.23 | D |  |
| Share Option (right to buy) | <sup>(3)</sup> | 2035-06-17 | Common Shares | 46392 | $1.84 | D |  |

---

### Footnotes:

(1) Includes 52,905 common shares underlying outstanding restricted share units.

(2) The share option is fully vested.

(3) The share option will fully vest on June 17, 2026.

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/ Matthias Maurer, attorney-in-fact for Monika Buetler  
**Date:** 2026-03-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**